Cue Biopharma, Inc. (CUE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cue Biopharma reported revenue of $27.5M, up 195.7% from $9.3M the year before. Net income was -$26.6M (a -96.9% net margin), or -$8.40 per diluted share. Operating margin was -96.7%. Operating activities generated -$21.7M of cash, leaving -$21.9M of free cash flow. At fiscal year end, Cue Biopharma held $42.2M in total assets against $15.8M in total liabilities, including $27.1M of cash and equivalents.
Open the full interactive Cue Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Cue Biopharma Key Stats
| Share Price | $19.57 |
|---|---|
| Market Cap | $124.1M |
| Revenue YoY Growth | +195.8% |
| 52-Week Range | $5.31 – $37.84 |
| Shares Outstanding | 6.3 million (basic, 2026 Q2) |
Cue Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2M | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Operating Income | -$45.0M | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.6M |
| Pre-Tax Income | -$44.6M | -$43.7M | -$53.0M | -$50.7M | -$40.7M | -$26.1M |
| Income Tax | $206,250 | $495,000 | $0 | — | — | $500,000 |
| Net Income | -$44.8M | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| Diluted EPS | -$46.80 | -$42.30 | -$44.70 | -$33.30 | -$21.60 | -$8.40 |
Cue Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.1M | $21.9M | $5.7M | $7.9M |
| Net Income | -$7.4M | $1.6M | -$5.2M | -$153.1M |
| Diluted EPS | -$2.10 | $0.02 | -$1.08 | -$24.14 |
Cue Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $74.9M | $64.4M | $51.6M | $48.5M | $22.5M | $27.1M |
| Current Assets | $87.5M | $68.5M | $77.2M | $51.5M | $25.1M | $37.0M |
| Total Assets | $99.5M | $83.4M | $91.3M | $61.5M | $32.2M | $42.2M |
| Current Liabilities | $16.3M | $12.8M | $11.5M | $17.1M | $13.7M | $13.5M |
| Total Long-Term Debt | — | — | $10.0M | $8.2M | — | — |
| Total Liabilities | $20.6M | $17.9M | $25.6M | $24.4M | $14.7M | $15.8M |
| Shareholders' Equity | $78.9M | $65.5M | $65.7M | $37.1M | $17.5M | $26.4M |
Cue Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$32.5M | -$38.8M | -$41.8M | -$40.0M | -$36.3M | -$21.7M |
| Cash From Investing | $4.5M | $9.1M | -$24.6M | $25.0M | $32,000 | $75,000 |
| Cash From Financing | $58.6M | $19.2M | $53.7M | $11.9M | $10.2M | $26.3M |
| Free Cash Flow | -$33.1M | -$39.8M | -$42.0M | -$40.0M | -$36.4M | -$21.9M |
Figures from Cue Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cue Biopharma financials page for every line item.
Cue Biopharma Company Profile
| Ticker | CUE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001645460 |
Frequently Asked Questions
What was Cue Biopharma's revenue in fiscal 2025?
Cue Biopharma (CUE) reported revenue of $27.5M for fiscal 2025.
What is Cue Biopharma's annual revenue history?
Cue Biopharma's annual revenue by fiscal year: 2020: $3.2M; 2021: $14.9M; 2022: $1.2M; 2023: $5.5M; 2024: $9.3M; 2025: $27.5M.
What was Cue Biopharma's net income in fiscal 2025?
Cue Biopharma reported net income of -$26.6M for fiscal 2025.
What was Cue Biopharma's earnings per share (EPS) in fiscal 2025?
Cue Biopharma's diluted EPS was -$8.40 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cue Biopharma generate in fiscal 2025?
Cue Biopharma generated -$21.9M of free cash flow in fiscal 2025.
What was Cue Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Cue Biopharma reported revenue of $7.9M.
How many shares of Cue Biopharma are outstanding?
Cue Biopharma reported a weighted average of 6.3 million basic shares outstanding in 2026 Q2.
What is Cue Biopharma's market cap?
Based on its latest closing price, Cue Biopharma (CUE) has a market capitalization of about $124.1M.
When does Cue Biopharma's fiscal year end?
Cue Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Cue Biopharma headquartered?
Cue Biopharma lists its business address in Boston, Massachusetts in its SEC filings.